Skip to main content


We're creating a new version of this page. See preview

  • Poster presentation
  • Open Access

PB.2. Axillary node ultrasound in breast cancer: which threshold for 'diffuse cortical thickening' predicts node metastasis?

  • 1,
  • 1 and
  • 1
Breast Cancer Research201416 (Suppl 1) :P18

  • Published:


  • Sentinel Node
  • Positive Predictive Value
  • Sentinel Node Biopsy
  • Needle Sampling
  • Axillary Clearance


There is variation in the literature and between breast units in the diffuse cortical thickening (DCT) threshold used for preoperative lymph node needle sampling. In our centre, needle sampling is performed in patients with DCT of 2 mm and above (LN3 of an LN1 to LN5 ultrasound classification). Results triage patients to appropriate axillary surgery: sentinel node biopsy or axillary clearance. This study investigates our 2 mm needle sampling threshold, to determine whether we can safely increase to 2.3 or 3 mm as used in some centres.


The authors performed a retrospective audit reviewing multidisciplinary team meeting records and ultrasound images of all invasive breast cancer patients with LN3 nodes diagnosed and operated upon in 2012 and 2013. Positive predictive value (PPV) was calculated for DCT ranges and a post-test probability of a malignant needle sample, and then a surgical yield of greater than two metastatic nodes.


A total of 223 female patients had an LN3 result and underwent needle sampling. The PPV for a malignant needle sample for DCT in the ranges 2.0 to 2.29 mm, 2.3 to 2.99 mm and ≥3.0 mm were 4.1% (1/24), 10.8% (12/111) and 17.4% (15/86). The PPV for a surgical yield of greater than two metastatic nodes in the ranges 2.0 to 2.29 mm, 2.3 to 2.99 mm and ≥3.0 mm were 16.6% (4/24), 4.5% (5/111) and 9.3%(8/86).


The 2 mm threshold leads to more accurate patient triage to appropriate axillary surgery, but requires many patients to undergo needle sampling for a small positive yield. Even the 2 mm DCT threshold does not identify all patients with bulky (>2 nodes) metastatic disease.

Authors’ Affiliations

Gateshead Hospitals NHS Trust, Gateshead, UK


© Hamilton et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.